特发性肺纤维化抗纤维化治疗资格取决于肺功能检测所用预测方程
本研究比较不同常用参考方程对特发性肺纤维化(IPF)患者肺功能预测值及公共资助治疗资格的影响。临床医生在评估资助阈值附近患者时应注意此变异。
要点
- 不同参考方程导致%FVC和%TLco预测值差异显著。
- IPF患者资助治疗资格随方程变化为73.6%-82.8%。
- 评估资助阈值附近患者时需注意方程选择的影响。
核心结论
- 不同参考方程间存在显著变异,影响公共资助治疗的可及性。
研究设计与样本
- 分析大型一般呼吸实验室和澳大利亚IPF登记数据库的FVC和TLco测量值,使用多种方程计算预测值。
主要发现
- AIPFR数据库545例结果中,%FVC≥50%从Roca的73%增至Quanjer(ECSC)的94%,%TLco≥30%从Paoletti的87%增至Miller的96%,总体资助资格在ILP中心间为73.6%至82.8%。
关键数值与推荐
- 澳大利亚资助标准:%FVC≥50%、%TLco≥30%、FEV1/FVC比值>0.7。
临床怎么用
- 临床医生在评估患者是否达到公共资助阈值时,应意识到参考方程选择带来的变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Publicly funded therapy for idiopathic pulmonary fibrosis (IPF) relies on percentage predicted values from pulmonary function testing, for example Australian patients must have a forced vital capacity ≥50% (%FVC), transfer factor of the lung for carbon monoxide ≥ 30% (%TLco) and forced expiratory volume in 1 s (FEV1 )/FVC ratio > 0.7. Despite defined cut-off values, no jurisdiction prescribes a reference equation for use; multiple equations exist. We hypothesized that access to subsidized treatment varies depending on the chosen equation. The %FVC and %TLco from different commonly used reference equations across general respiratory patients, and IPF-specific patients, were compared. METHODS: FVC and TLco measurements from a large general respiratory laboratory and the Australian Idiopathic Pulmonary Fibrosis Registry (AIPFR) database were analysed using multiple equations. Differences between %FVC and %TLco for each equation were calculated, with particular interest in classification of patients (%) at the threshold for subsidized treatment. RESULTS: A total of 20 378 general respiratory database results were analysed. The %FVC ≥ 50% increased from 86% with the Roca equation to 96% with Quanjer (European Coal and Steal Community, ECSC) and %TLco≥30% increased from 91% with Paoletti to 98% with Thompson. However, overall increase in eligibility for subsidized treatment was modest, varying from 48.2% to 49.2%. A total of 545 AIPFR database results were analysed. The %FVC ≥ 50% increased from 73% with Roca to 94% with Quanjer (ECSC) and %TLco≥30% increased from 87% with Paoletti to 96% with Miller. Overall eligibility for subsidized treatment in the AIPFR group varied from 73.6% to 82.8% between surveyed interstitial lung disease (ILD) centres based entirely on the equation used. CONCLUSION: Substantial variability exists between reference equations, impacting access to subsidized treatment. Treating clinicians should be aware of this when assessing patients around public funding thresholds.
引用
- Burgess A, Goon K, Brannan JD, et al. Eligibility for anti-fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing. Respirology. 2019. PMID: 30924257. doi:10.1111/resp.13540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。